| B35 | Week 72 outcomes and COVID-19 impact from The BRAAVE 2020 study: a randomized switch to B/F/TAF in African American adults living with HIV | E-poster | Regimen simplification and switch studies |
| B35 | Successfully (and safely) enrolling a multi-center HIV antiretroviral clinical trial during the COVID-19 pandemic: lessons learned from Kenya | E-poster | Regimen simplification and switch studies |
| B35 | DTG+3TC in GEMINI-1&-2: HIV-1 replication at <50 c/mL and VL blips through 144 weeks | E-poster | Regimen simplification and switch studies |
| B35 | Metabolic health outcomes at week 96 in the TANGO Study, comparing a switch to DTG/3TC versus maintenance of TAF-based regimens | E-poster | Regimen simplification and switch studies |
| B35 | Low risk of losing the undetectable viral load status in people with HIV switching to dual therapy | E-poster | Regimen simplification and switch studies |
| B35 | Transition to DTG in Cote d'Ivoire: are women being left behind? | E-poster | Regimen simplification and switch studies |
| B35 | Impact of baseline NNRTI pretreatment resistance mutations on risk of virologic failure of RPV-based dual therapies | E-poster | Regimen simplification and switch studies |
| B35 | 24 week randomised study of switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N | E-poster | Regimen simplification and switch studies |
| B33 | Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) | Oral abstract session with live Q&A | ART in highly treatment-experienced people |
| B33 | Transition to TLD leads to decreased rates of virologic failure among PLWH in sub-Saharan Africa | E-poster | ART in highly treatment-experienced people |